ABSTRACT
The PIK3CA-related overgrowth spectrum (PROS) encompasses various conditions caused by mosaic activating PIK3CA variants. PIK3CA somatic variants are also involved in various cancer types. Some generalized overgrowth syndromes are associated with an increased risk of Wilms tumor (WT). In PROS, abdominal ultrasound surveillance has been advocated to detect WT. We aimed to determine the risk of embryonic and other types of tumors in patients with PROS in order to evaluate surveillance relevance. We searched the clinical charts from 267 PROS patients for the diagnosis of cancer, and reviewed the medical literature for the risk of cancer. In our cohort, six patients developed a cancer (2.2%), and Kaplan Meier analyses estimated cumulative probabilities of cancer occurrence at 45 years of age was 5.6% (95% CI = 1.35%-21.8%). The presence of the PIK3CA variant was only confirmed in two out of four tumor samples. In the literature and our cohort, six cases of Wilms tumor/nephrogenic rests (0.12%) and four cases of other cancers have been reported out of 483 proven PIK3CA patients, in particular the p.(His1047Leu/Arg) variant. The risk of WT in PROS being lower than 5%, this is insufficient evidence to recommend routine abdominal imaging. Long-term follow-up studies are needed to evaluate the risk of other cancer types, as well as the relationship with the extent of tissue mosaicism and the presence or not of the variant in the tumor samples.
Subject(s)
Kidney Neoplasms , Wilms Tumor , Humans , Mutation , Early Detection of Cancer , Growth Disorders/diagnosis , Wilms Tumor/diagnosis , Wilms Tumor/epidemiology , Wilms Tumor/genetics , Class I Phosphatidylinositol 3-Kinases/geneticsABSTRACT
BACKGROUND: Chromosome 15q24 microdeletion is a rare genetic disorder, and the skin manifestations are poorly documented. OBJECTIVES: In this cross-sectional observational study using social media (Facebook), we investigated the prevalence of atopic dermatitis in 15q24 microdeletion syndrome. MATERIALS & METHODS: Parents and caregivers of a child with the syndrome were asked to participate using a validated self-reporting questionnaire. RESULTS: In total, 60 participants completed the questionnaire. The prevalence of atopic dermatitis was 35% among patients with chromosome 15q24 deletion. Few patients received treatment according to international guidelines. CONCLUSION: We describe the largest cohort of patients with 15q24 microdeletion syndrome, revealing a high prevalence of atopic dermatitis. Patients with 15q24 microdeletion syndrome should undergo dermatological evaluation for screening and management of atopic dermatitis. Approaching individuals via social media is a successful strategy, resulting in good information which may be used to counsel families.
Subject(s)
Dermatitis, Atopic , Social Media , Child , Humans , Dermatitis, Atopic/genetics , Cross-Sectional Studies , Chromosome Deletion , Rare DiseasesABSTRACT
In infants, pruritus is frequently considered as absent because they do not scratch themselves. Because pruritus could induce severe adverse effects in this vulnerable population, we aimed to review existing evidence on the ability of young infants to experience itch and on how to assess itch-related discomfort in this population. A literature review was performed (Pubmed, Google Scholar). Neurological itch pathways are well described. Skin development starts early during gestation. At 34 weeks of gestation, skin is almost complete while skin adaptations occur after birth. Newborn skin is neurologically functional, including the ability for young infants to feel pain. Similarities and interactions between pain and pruritus support the hypothesis that infants could feel pruritus. However, the existence of pruritus in infants has never been evidenced. Many itchy conditions can affect them, suggesting non-negligible prevalence of infant pruritus among which atopic dermatitis (AD) is the most studied disease. Studies reported a negative impact of AD on children and their families. There is no existing validated method to assess pruritus in infants, although they may feel pruritus and chronic pruritus can lead to serious adverse effects. To appropriately diagnose pruritus appears of great interest among young infants. Development of a method is required to this aim.
Subject(s)
Pruritus/pathology , Biomedical Research , Humans , Infant , Pain/complications , Pain/physiopathology , Pruritus/epidemiology , Pruritus/etiology , Pruritus/physiopathology , Skin/pathologyABSTRACT
Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas-related GPCRs and unexpected new pathways need to be also explored.
Subject(s)
Pruritus , Receptors, Neurokinin-1 , Humans , Molecular Targeted Therapy , Pruritus/drug therapyABSTRACT
Pruritus is a common symptom of bullous pemphigoid (BP), but has been poorly studied. The aim of this study was to analyse the characteristics of pruritus in patients with BP and its impact on their quality of life. A multicentre prospective observational study (in 15 French hospitals) was performed. A total of 60 patients were included, with a mean age of 77.4 years. Pruritus occurred daily in 85% of patients, with a mean pruritus intensity of 5.2/10. Tingling sensations were present in 72.4% of patients and burning sensations in 68.9%. Pruritus was exacerbated by stress, fatigue and xerosis. The mean ItchyQol score was 56.2/110 and the mean 5-D Itch Scale score was 16.5/25. The severity of pruritus was not related to age, sex, BP activity score, eosinophilia, or anti-BP230 and anti-BP180 autoantibodies. This study revealed that pruritus in BP is poorly tolerated and is an important cause of impaired quality of life.
Subject(s)
Pemphigoid, Bullous , Quality of Life , Aged , Autoantibodies , Autoantigens , Dystonin , Humans , Non-Fibrillar Collagens , Pemphigoid, Bullous/diagnosis , Pemphigoid, Bullous/epidemiology , Prospective Studies , Pruritus/diagnosis , Pruritus/epidemiology , Pruritus/etiologyABSTRACT
We report the case of a 5-year-old girl with congenital right-sided facial hemihypertrophy and right hemi-macroglossia with lingual mucosal neuromas. The segmental presentation of findings suggested the diagnosis of congenital infiltrating lipomatosis of the face (CILF), which belongs within the PIK3CA-related overgrowth spectrum (PROS). This was confirmed by genetic analysis showing a mosaic mutation in PIK3CA H1047R. CILF/PROS should be considered in the differential diagnosis of mucosal neuromas.
Subject(s)
Lipomatosis , Neuroma , Child, Preschool , Class I Phosphatidylinositol 3-Kinases/genetics , Face , Facial Asymmetry , Female , Humans , MutationSubject(s)
Pemphigus/epidemiology , Adolescent , Adult , Age Distribution , Age Factors , Aged , Aged, 80 and over , Child , Child, Preschool , Female , France/epidemiology , Humans , Incidence , Infant , Infant, Newborn , Male , Middle Aged , Mortality/trends , Prognosis , Sex Factors , Young AdultABSTRACT
Pruritus is a frequent symptom in systemic sclerosis (SSc), with a prevalence of 40-65%, but its pathophysiology is poorly understood. This study investigated the immunological component of pruritus. Fifty-six patients with SSc responded to a standardized questionnaire regarding both SSc disease and pruritus characteristics. Among patients with SSc, those with pruritus did not display a particular immunological profile (inflammatory, humoral, and/or cellular factors), but pruritus was, in most cases, concomitant with the development of SSc. Thus, pruritus characteristics were evaluated further, according to the detection of anti-centromere autoantibodies (ACA), into ACA+ (n = 17) and ACA- (n = 19). The ACA+ subgroup was characterized by a longer evolution of SSc and pruritus, pruritus present outside the sclerotic area, and a shorter daily duration of pruritus. In conclusion, the concomitant appearance of the 2 processes and the differences observed between ACA+ and ACA- subgroups support the presence of an immunological component in pruritus.
Subject(s)
Antibodies, Antinuclear/blood , Autoimmunity , Pruritus/immunology , Scleroderma, Systemic/immunology , Aged , Biomarkers/blood , Female , Humans , Male , Middle Aged , Pruritus/diagnosis , Registries , Retrospective Studies , Scleroderma, Systemic/complications , Scleroderma, Systemic/diagnosis , Serologic Tests , Severity of Illness Index , Surveys and Questionnaires , Time FactorsSubject(s)
Neurofibromatosis 1/diagnosis , Parents/psychology , Patients/psychology , Stress Disorders, Post-Traumatic/diagnosis , Adaptation, Psychological , Adolescent , Adult , Aged , Child , Child, Preschool , Cost of Illness , Emotions , Female , Humans , Male , Middle Aged , Neurofibromatosis 1/psychology , Stress Disorders, Post-Traumatic/psychology , Surveys and Questionnaires , Young AdultABSTRACT
PURPOSE: Postzygotic activating mutations of PIK3CA cause a wide range of mosaic disorders collectively referred to as PIK3CA-related overgrowth spectrum (PROS). We describe the diagnostic yield and characteristics of PIK3CA sequencing in PROS. METHODS: We performed ultradeep next-generation sequencing (NGS) of PIK3CA in various tissues from 162 patients referred to our clinical laboratory and assessed diagnostic yield by phenotype and tissue tested. RESULTS: We identified disease-causing mutations in 66.7% (108/162) of patients, with mutant allele levels as low as 1%. The diagnostic rate was higher (74%) in syndromic than in isolated cases (35.5%; P = 9.03 × 10-5). We identified 40 different mutations and found strong oncogenic mutations more frequently in patients without brain overgrowth (50.6%) than in those with brain overgrowth (15.2%; P = 0.00055). Mutant allele levels were higher in skin and overgrown tissues than in blood and buccal samples (P = 3.9 × 10-25), regardless of the phenotype. CONCLUSION: Our data demonstrate the value of ultradeep NGS for molecular diagnosis of PROS, highlight its substantial allelic heterogeneity, and confirm that optimal diagnosis requires fresh skin or surgical samples from affected regions. Our findings may be of value in guiding future recommendations for genetic testing in PROS and other mosaic conditions.Genet Med advance online publication 02 February 2017.